Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA breakthrough therapy designation in IPF
17 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that for the first time the U.S. Food & Drug Administration has granted Breakthrough Therapy designation for a treatment in idiopathic pulmonary fibrosis...